The Effect of Paraprotein on Platelet Aggregation

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2014 Jan 8

PMID 24395751

Citations 3

Authors

Irena Djunic

Ivo Elezovic

Vesna Ilic

Nadezda Milosevic-Jovcic

Jelena Bila

Nada Suvajdzic-Vukovic

Darko Antic

Ana Vidovic

Dragica Tomin

Affiliations

Soon will be listed here.

Abstract

Background: Some patients with paraproteinemia have platelet aggregation disorders and the aim of this study was to examine disturbance of platelet aggregation in healthy blood donors by isolated paraprotein in vitro.

Methods: Using Rivanol, paraprotein was separated from the serum of ten patients with paraproteinemia, who had decreased platelet aggregation with several inducers. Platelet aggregation in ten healthy donors was measured with and without addition of the isolated induced paraprotein. The test was repeated with added human immunoglobulins for intravenous use.

Results: Average of maximal levels of platelet aggregation has been significantly decreased in plasma rich in platelets (PRP) of healthy donors after addition of paraprotein when inducers are used: adenosine diphosphate (ADP) (P = 0.007), collagen (COL) (P = 0.008), ristocetin (RIS) (P = 0.001), and epinephrine (EPI) (P = 0.002). Average of latent time of platelet aggregation was significantly prolonged in healthy donors after addition of paraprotein with inducers: COL (P = 0.008), RIS (P = 0.008) and EPI (P = 0.006) while addition of human immunoglobulins caused no change in platelet aggregation. In comparison, when human immunoglobulins were added, maximal platelet aggregation and latent time did not change significantly. Paraprotein isolated from patients with paraproteinamia, who had decrease platelet aggregation, had significantly decreased platelet aggregation when added to PRP of healthy donors, in vitro.

Conclusion: Platelet aggregation was not significantly changed was confirmed with addition of human immunoglobulins.

Citing Articles

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.

Ma R, Zhang Q, Liu Y, Li H, Chen H, Zhang Q Clin Exp Med. 2024; 24(1):210.

PMID: 39230837 PMC: 11374909. DOI: 10.1007/s10238-024-01477-y.

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance.

Moreno D, Rosinol L, Cibeira M, Blade J, Fernandez de Larrea C Cancers (Basel). 2021; 13(20).

PMID: 34680279 PMC: 8533809. DOI: 10.3390/cancers13205131.

Long-Term Remission of Acquired Von-Willebrand's Disease and Platelet Dysfunction after High-Dose Melphalan in a Patient with Multiple Myeloma.

Stratmann J, Gundermann S, Geisen C, Dukat A, Miesbach W Int J Hematol Oncol Stem Cell Res. 2019; 13(1):7-11.

PMID: 31205622 PMC: 6557967.

References

Porter R . The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J. 1959; 73:119-26. PMC: 1197021. DOI: 10.1042/bj0730119. View

Edelman G . Antibody structure and molecular immunology. Science. 1973; 180(4088):830-40. DOI: 10.1126/science.180.4088.830. View

Freedman M, Merrett R, Pruzanski W . Human monoclonal immunoglobulins with antibody-like activity. Immunochemistry. 1976; 13(3):193-202. DOI: 10.1016/0019-2791(76)90215-9. View

Kappeler R, Krebs A, Riva G . [Clinical manifestations of Waldenstrom's macroglobulinemia; report of 21 cases & review of the literature]. Helv Med Acta. 1958; 25(1):54-101 contd. View

Spicka I, Cieslar P, Dyr J, Matousova O . [Hemostasis disorders in monoclonal gammopathies]. Sb Lek. 1991; 93(9-10):277-86. View

Robert F, Mignucci M, McCurdy S, Maldonado N, Lee J . Hemostatic abnormalities associated with monoclonal gammopathies. Am J Med Sci. 1993; 306(6):359-66. DOI: 10.1097/00000441-199312000-00001. View

Born G, Cross M . THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963; 168:178-95. PMC: 1359417. DOI: 10.1113/jphysiol.1963.sp007185. View

Spicka I, Rihova Z, Kvasnicka J, Cieslar P, Prochazka B, Klener P . Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies-another mechanism of M-protein interference with hemostasis. Thromb Res. 2004; 112(5-6):297-300. DOI: 10.1016/j.thromres.2003.12.007. View

Shinagawa A, Kojima H, Berndt M, Kaneko S, Suzukawa K, Hasegawa Y . Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost. 2005; 93(5):889-96. DOI: 10.1160/TH04-03-0193. View

10.

Virella G, Lechner M . Two IgM paraproteins differing in carbohydrate content in a patient with Waldenström's macroglobulinemia. Clin Chim Acta. 1976; 67(2):137-44. DOI: 10.1016/0009-8981(76)90252-7. View

11.

Dighiero G . Autoimmunity and B-cell malignancies. Hematol Cell Ther. 1998; 40(1):1-9. View

12.

Decourt C, Cogne M, Rocca A . Structural peculiarities of a truncated V kappa III immunoglobulin light chain in myeloma with light chain deposition disease. Clin Exp Immunol. 1996; 106(2):357-61. PMC: 2200580. DOI: 10.1046/j.1365-2249.1996.d01-841.x. View

13.

Sagan Z . The application of rivanol for serum transferrin and immunoglobulin G determination. Clin Chim Acta. 1968; 21(2):225-30. DOI: 10.1016/0009-8981(68)90131-9. View

14.

Garver F, Chang L, Mendicino J, Isobe T, Osserman E . Primary structure of a deleted human lambda type immunoglobulin light chain containing carbohydrate: protein Sm lambda. Proc Natl Acad Sci U S A. 1975; 72(11):4559-63. PMC: 388762. DOI: 10.1073/pnas.72.11.4559. View

15.

Jefferis R, Lund J . Glycosylation of antibody molecules: structural and functional significance. Chem Immunol. 1997; 65:111-28. View

16.

MEJBAUM-KATZENELLENBOGEN W . [Turbidimetric micromethod of determination of proteins with tannin]. Acta Biochim Pol. 1955; 2(3):279-96. View

17.

Recht B, Frangione B, Franklin E, van Loghem E . Structural studies of a human gamma 3 myeloma protein (Goe) that binds staph protein A. J Immunol. 1981; 127(3):917-23. View

18.

DiMinno G, CORAGGIO F, Cerbone A, Capitanio A, Manzo C, Spina M . A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest. 1986; 77(1):157-64. PMC: 423321. DOI: 10.1172/JCI112270. View

19.

Amzel L, POLJAK R . Three-dimensional structure of immunoglobulins. Annu Rev Biochem. 1979; 48:961-97. DOI: 10.1146/annurev.bi.48.070179.004525. View

20.

Jefferis R, Reimer C, Skvaril F, de Lange G, Goodall D, Bentley T . Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study. Immunol Lett. 1992; 31(2):143-68. DOI: 10.1016/0165-2478(92)90141-a. View